NAMPT
Nicotinamide phosphoribosyltransferase
As of the edition of 20 October 2026, NAMPT (nicotinamide phosphoribosyltransferase, UniProt P43490) has 3 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43490
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 85
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue
- Registered trials of its drugs
- 6
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Daporinad | Went quiet | Phase 2 | none listed |
| Padnarsertib | Stopped | Phase 1 | none listed |
| Teglarinad | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Karyopharm Therapeutics | Route A |
| Antengene | Route A |
| Valerio Therapeutics | Route A |
The other 1 company at NAMPT
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at NAMPT, ranked, with the facts behind eachRequest access. Nothing is shown until you do.